封面
市场调查报告书
商品编码
1317666

头颈癌治疗市场:按产品(博莱霉素、西妥昔单抗、多西他赛)、按药物类别(化疗​​、免疫疗法、放射线治疗)、最终用户 - 2023 年至 2030 年全球预测

Head & Neck Cancer Drugs Market by Product (Bleomycin, Cetuximab, Docetaxel), Drug Class (Chemotherapy, Immunotherapy, Radiation therapy), End User - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年全球头颈癌治疗市场将达13.5641亿美元,复合年增长率为15.41%,预计2030年将达37.0386亿美元。

FPNV定位矩阵

FPNV定位矩阵对于评估全球头颈癌治疗市场至关重要。透过检查业务策略和产品满意度的关键指标,我们对供应商进行全面评估,使您能够根据您的特定需求做出明智的资讯。这种进阶分析将供应商分为四个像限,并取得了不同程度的成功:前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市占率分析

市场占有率分析可以深入了解供应商在特定市场领域的当前地位。比较供应商对总收入、基本客群和其他关键指标的贡献,可以帮助公司更好地了解他们在争夺市场份额时的表现以及面临的情况。该分析还揭示了特定行业的竞争程度、累积和合併的优势以及研究基准年的合併特征。

本报告提供了以下几点见解:

1. 市场渗透率:提供有关主要企业所服务的市场的全面资讯。

2. 市场开发:提供有关利润丰厚的新兴市场的详细资讯,并分析其在成熟市场的渗透率。

3. 市场多元化:提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4.市场趋势:全面了解COVID-19、俄罗斯-乌克兰衝突和高通膨的累积影响。

5.竞争评估与资讯:对主要企业的市场占有率、策略、产品、认证、法规状况、专利状况、製造能力等进行综合评估。

6. 产品开发与创新:提供对未来技术、研发活动和突破性产品开发的见解。

本报告回答了以下问题:

1.全球头颈癌治疗药物市场规模及预测为何?

2.在预测期内,COVID-19 对全球头颈癌治疗药物市场的阻碍因素与影响为何?

3.在预测期内,全球头颈癌药物市场应投资哪些产品/细分市场/用途/领域?

4.你们在全球头颈癌药物市场的竞争策略是什么?

5.全球头颈癌药物市场的技术趋势和法律规范是什么?

6.全球头颈癌治疗药物市场主要厂商的市占率为何?

7. 哪些型态和策略性措施被认为适合进入全球头颈癌药物市场?

目录

第1章前言

第2章调查方法

第3章执行摘要

第4章市场概况

第5章市场洞察

  • 市场动态
    • 促进因素
      • 全球头颈癌发生率上升
      • 增加政府和私营部门对癌症治疗的配合措施
      • 头颈癌药物的核准增加
    • 抑制因素
      • 药品很贵
    • 机会
      • 头颈癌药物的优惠报销
      • 后期管道药物开发的新投资
    • 任务
      • 与药物摄取相关的副作用
  • 市场趋势
  • COVID-19 的累积影响
  • 俄罗斯-乌克兰衝突的累积影响
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法律规范
  • 客户客製化

第6章头颈癌治疗市场:按产品

  • 介绍
  • 博来霉素
  • 西妥昔单抗
  • 多西紫杉醇
  • 爱必妥(西妥昔单抗)
  • Hydrea(羟基脲)
  • 羟基脲
  • Keytruda(派姆单抗)
  • 甲胺蝶呤
  • 纳武单抗
  • Opdivo(纳武单抗)
  • 帕博利珠单抗
  • 泰索帝(多西紫杉醇)
  • Trexol(甲胺蝶呤)

第7章头颈癌治疗药物市场:依药效分类

  • 介绍
  • 化学处理
  • 免疫疗法
  • 放射治疗
  • 外科手术
  • 标靶治疗

第8章头颈癌药物市场:依最终用户分类

  • 介绍
  • 癌症研究
  • 诊所
  • 医院

第9章北美和南美头颈癌药物市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太地区头颈癌药物市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第11章欧洲、中东和非洲头颈癌药物市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第12章竞争形势

  • FPNV定位矩阵
  • 市占率分析:主要企业
  • 竞争情境分析:主要企业

第13章上市公司名单

第14章附录

  • 讨论指南
  • 关于许可证和定价
Product Code: MRR-43676CF423BF

The Global Head & Neck Cancer Drugs Market is forecasted to grow significantly, with a projected USD 1,356.41 million in 2023 at a CAGR of 15.41% and expected to reach a staggering USD 3,703.86 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Head & Neck Cancer Drugs Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Head & Neck Cancer Drugs Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Product, market is studied across Bleomycin, Cetuximab, Docetaxel, Erbitux (Cetuximab), Hydrea (Hydroxyurea), Hydroxyurea, Keytruda (Pembrolizumab), Methotrexate, Nivolumab, Opdivo (Nivolumab), Pembrolizumab, Taxotere (Docetaxel), and Trexall (Methotrexate). The Trexall (Methotrexate) is projected to witness significant market share during forecast period.

Based on Drug Class, market is studied across Chemotherapy, Immunotherapy, Radiation therapy, Surgery, and Targeted Therapy. The Radiation therapy is projected to witness significant market share during forecast period.

Based on End User, market is studied across Cancer Research Institutes, Clinics, and Hospitals. The Cancer Research Institutes is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.74% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Head & Neck Cancer Drugs Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Head & Neck Cancer Drugs Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Head & Neck Cancer Drugs Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Head & Neck Cancer Drugs Market?

4. What is the competitive strategic window for opportunities in the Global Head & Neck Cancer Drugs Market?

5. What are the technology trends and regulatory frameworks in the Global Head & Neck Cancer Drugs Market?

6. What is the market share of the leading vendors in the Global Head & Neck Cancer Drugs Market?

7. What modes and strategic moves are considered suitable for entering the Global Head & Neck Cancer Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Head & Neck Cancer Drugs Market, by Product, 2022 vs 2030
  • 4.3. Head & Neck Cancer Drugs Market, by Drug Class, 2022 vs 2030
  • 4.4. Head & Neck Cancer Drugs Market, by End User, 2022 vs 2030
  • 4.5. Head & Neck Cancer Drugs Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence of head and neck cancer all across the globe
      • 5.1.1.2. Rise in government and private body initiatives for cancer treatment
      • 5.1.1.3. Increased approval for head & neck cancer drugs
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of the drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Favorable reimbursements for head and neck cancer drugs
      • 5.1.3.2. New investments for developing late-stage pipeline drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse effect associated with the consumption of the drug
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Head & Neck Cancer Drugs Market, by Product

  • 6.1. Introduction
  • 6.2. Bleomycin
  • 6.3. Cetuximab
  • 6.4. Docetaxel
  • 6.5. Erbitux (Cetuximab)
  • 6.6. Hydrea (Hydroxyurea)
  • 6.7. Hydroxyurea
  • 6.8. Keytruda (Pembrolizumab)
  • 6.9. Methotrexate
  • 6.10. Nivolumab
  • 6.11. Opdivo (Nivolumab)
  • 6.12. Pembrolizumab
  • 6.13. Taxotere (Docetaxel)
  • 6.14. Trexall (Methotrexate)

7. Head & Neck Cancer Drugs Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Chemotherapy
  • 7.3. Immunotherapy
  • 7.4. Radiation therapy
  • 7.5. Surgery
  • 7.6. Targeted Therapy

8. Head & Neck Cancer Drugs Market, by End User

  • 8.1. Introduction
  • 8.2. Cancer Research Institutes
  • 8.3. Clinics
  • 8.4. Hospitals

9. Americas Head & Neck Cancer Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Head & Neck Cancer Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Head & Neck Cancer Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. List of Company Mentioned

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. HEAD & NECK CANCER DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. HEAD & NECK CANCER DRUGS MARKET SIZE, 2022 VS 2030
  • FIGURE 3. HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2022 VS 2030 (%)
  • FIGURE 5. HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2022 VS 2030 (%)
  • FIGURE 6. HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2022 VS 2030 (%)
  • FIGURE 7. HEAD & NECK CANCER DRUGS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 8. HEAD & NECK CANCER DRUGS MARKET DYNAMICS
  • FIGURE 9. HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 16. HEAD & NECK CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 17. HEAD & NECK CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. HEAD & NECK CANCER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 5. HEAD & NECK CANCER DRUGS MARKET SIZE, BY BLEOMYCIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. HEAD & NECK CANCER DRUGS MARKET SIZE, BY CETUXIMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. HEAD & NECK CANCER DRUGS MARKET SIZE, BY DOCETAXEL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. HEAD & NECK CANCER DRUGS MARKET SIZE, BY ERBITUX (CETUXIMAB), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. HEAD & NECK CANCER DRUGS MARKET SIZE, BY HYDREA (HYDROXYUREA), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. HEAD & NECK CANCER DRUGS MARKET SIZE, BY HYDROXYUREA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. HEAD & NECK CANCER DRUGS MARKET SIZE, BY KEYTRUDA (PEMBROLIZUMAB), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. HEAD & NECK CANCER DRUGS MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. HEAD & NECK CANCER DRUGS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. HEAD & NECK CANCER DRUGS MARKET SIZE, BY OPDIVO (NIVOLUMAB), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. HEAD & NECK CANCER DRUGS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. HEAD & NECK CANCER DRUGS MARKET SIZE, BY TAXOTERE (DOCETAXEL), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. HEAD & NECK CANCER DRUGS MARKET SIZE, BY TREXALL (METHOTREXATE), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 19. HEAD & NECK CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. HEAD & NECK CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. HEAD & NECK CANCER DRUGS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. HEAD & NECK CANCER DRUGS MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. HEAD & NECK CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. HEAD & NECK CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. INDIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59. INDIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. INDONESIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. INDONESIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. INDONESIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. JAPAN HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. JAPAN HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. JAPAN HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. MALAYSIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. MALAYSIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. MALAYSIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. PHILIPPINES HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. PHILIPPINES HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. PHILIPPINES HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. SINGAPORE HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. SINGAPORE HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. SINGAPORE HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. SOUTH KOREA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. SOUTH KOREA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. SOUTH KOREA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. TAIWAN HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. TAIWAN HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. TAIWAN HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. THAILAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. THAILAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. THAILAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. VIETNAM HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. VIETNAM HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. VIETNAM HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. DENMARK HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. DENMARK HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. DENMARK HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. EGYPT HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. EGYPT HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. EGYPT HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. FINLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 99. FINLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. FINLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. FRANCE HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. FRANCE HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. FRANCE HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. GERMANY HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 105. GERMANY HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. GERMANY HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. ISRAEL HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 108. ISRAEL HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. ISRAEL HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. ITALY HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. ITALY HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. ITALY HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. NETHERLANDS HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 114. NETHERLANDS HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 115. NETHERLANDS HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. NIGERIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 117. NIGERIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. NIGERIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. NORWAY HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 120. NORWAY HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 121. NORWAY HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. POLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 123. POLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. POLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. QATAR HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. QATAR HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 127. QATAR HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 128. RUSSIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 129. RUSSIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. RUSSIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. SAUDI ARABIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 132. SAUDI ARABIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 133. SAUDI ARABIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. SOUTH AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 135. SOUTH AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. SOUTH AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. SPAIN HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 138. SPAIN HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. SPAIN HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. SWEDEN HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 141. SWEDEN HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. SWEDEN HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. SWITZERLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 144. SWITZERLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 145. SWITZERLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 146. TURKEY HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 147. TURKEY HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. TURKEY HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED ARAB EMIRATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 150. UNITED ARAB EMIRATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 151. UNITED ARAB EMIRATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 152. UNITED KINGDOM HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 153. UNITED KINGDOM HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 154. UNITED KINGDOM HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 155. HEAD & NECK CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 156. HEAD & NECK CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 157. HEAD & NECK CANCER DRUGS MARKET LICENSE & PRICING